Deepak Chopra Plans to Raise Awareness About Healing Potential of Psychedelics

Last week, Deepak Chopra revealed that he’d entered into a new partnership with MindMed (NEO: MMED) (OTCQB: MMEDF), which aligned with his continued interest in mind-body healing. MindMed is a clinical-stage biotech company that is researching psychedelic medicine.

In his statement, the self-care leader announced that the collaboration was for the public awareness of psychedelic research and public education, adding that while he didn’t believe psychedelics were a universal cure, they had a huge role to play in suicide prevention and the treatment of depression and post-traumatic stress disorder, among other conditions.

A phase 3 clinical trial conducted by MindMed found that when MDMA was administered in combination with therapy, it helped individuals with PTSD manage their symptoms. The trial noted that more than half of the participants in the test group didn’t qualify for a post-traumatic stress disorder diagnosis two months after MDMA therapy had been administered. However, therapists caution that the treatment can’t be recreated at home using street versions of ecstasy.

MDMA, or methylenedioxymethamphetamine, which is commonly known as molly or ecstasy, is a synthetic drug that is derived from amphetamine. The drug is known to produce effects such as enhanced sensory perception, reduced anxiety and mental stimulation. The drug works by enhancing the activity of three chemicals in the brain, namely norepinephrine, serotonin and dopamine. These chemicals play different roles in various functions including sleep, sexual activity, trust, appetite, energy levels, emotions and moods.

Individuals who use the substance have reported feeling uninhibited and energetic along with heightened sensations of smell, sound and touch, as well as feelings of clarity, openness, warmth and euphoria. The substance’s effects usually start about half an hour after ingesting the drug and last for anywhere between three to six hours, depending on the dose consumed.

During an interview with CNBC, Deepak Chopra stated that mental distress was the biggest pandemic in the world, noting that one individual committed suicide every 40 seconds. This, he said, was another reason why he wanted to raise awareness about psychedelics.

The interview’s host also noted that Chopra had a history of backing alternative treatments that were sometimes questioned by health-care providers. He asked the self-care leader what about his collaboration with the psychedelic medicine company was different from his other endeavors. Chopra replied that a simple online search would bring up various research and evidence on mindfulness and psychedelics, and the various uses and benefits that these substances possess.

The research coming through regarding the therapeutic benefits of psychedelics points to an exciting future of new therapies, especially given the readiness of companies such as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) to manufacture medicinal and functional psychedelic products.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.